The goal of the administrative core of the University of Colorado Lung Cancer SPORE is to provide outstanding administrative and fiscal support for the entire program effort and to provide the scientific leadership for the program. The administrative core will oversee all administrative and scientific activities of the SPORE program, review and regulate financial expenditures, develop and prepare reports. The Administrative core consists of the two SPORE principal investigators, Drs. Bunn and Miller;the SPORE executive director. Donna Berrier, a 40% grants manager/administrative assistant and 10% financial manager. This core will also develop and circulate research conference schedules, coordinate scientific review, schedule the monthly scientific meetings and aid project investigators in the preparation and publication of manuscripts as well as maintain a record of all publications emanating from this grant. It will oversee the planning and evaluation efforts including the scheduling of visits by the external advisors, the planning and coordinating of the yearly internal retreats and yearly NCI SPORE meetings, the scheduling of meetings and scientists, Executive Committee, Developmental Research Committee and Career Development Committee and the SPORE advocacy program.. The Administrative Core works with the SPORE investigators and NCI program staff to insure compliance with all federal regulations and reporting requirements. It will coordinate activities with the Cancer Center and with other SPORES to ensure that there is no redundancy, and to ensure joint projects are conducted in the most economical way. The Administrative Core will assist in community outreach efforts particularly with respect to public relations and community activities through the established Cancer Center mechanisms. The core provides support for the development and career development programs as well as Visiting scientist program. The Administrative core oversees the functioning of the other four core resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-18
Application #
8376668
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
18
Fiscal Year
2012
Total Cost
$160,380
Indirect Cost
$47,209
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Oweida, Ayman; Lennon, Shelby; Calame, Dylan et al. (2017) Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology 6:e1356153
Blakely, Collin M; Watkins, Thomas B K; Wu, Wei et al. (2017) Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49:1693-1704
Tan, Aik-Choon; Vyse, Simon; Huang, Paul H (2017) Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discov Today 22:72-84
Ziemke, Michael; Patil, Tejas; Nolan, Kyle et al. (2017) Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer 109:28-35
Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126
Gautschi, Oliver; Milia, Julie; Filleron, Thomas et al. (2017) Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 35:1403-1410
Li, Howard Y; McSharry, Maria; Bullock, Bonnie et al. (2017) The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunol Res 5:767-777
McCoach, C E; Blumenthal, G M; Zhang, L et al. (2017) Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol 28:2707-2714
Vaishnavi, Aria; Schubert, Laura; Rix, Uwe et al. (2017) EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res 77:3551-3563
Bruno, Tullia C; Ebner, Peggy J; Moore, Brandon L et al. (2017) Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. Cancer Immunol Res 5:898-907

Showing the most recent 10 out of 397 publications